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FFAR2 (GPR43) is a receptor for short-chain fatty acids (SCFAs), acetate and propionate. In the cur-
rent study, we investigate the molecular determinants contributing to receptor activation by endog-
enous ligands. Mutational analysis revealed several important residues located in transmembrane
domains (TM) 3, 4, 5, 6, and 7 for acetate binding. Interestingly, mutations that abolished acetate
activity, including the mutation in the well-conserved D(E)RY motif, could be rescued by a recently
identiﬁed synthetic allosteric agonist. These ﬁndings provide additional insight into agonist binding
and activation which may aid in designing allosteric ligands for targeting receptor function in var-
ious diseases.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction dyslipidemia and other metabolic disorders [7]. Clearly, a betterFree fatty acid receptor 2 (FFAR2), also known as GPR43, is a
member of the G-protein-coupled receptor (GPCR) superfamily
[1]. FFAR2 forms a subfamily with two other closely related recep-
tors, FFAR1 (GPR40) and FFAR3 (GPR41) [1]. All three receptors can
be activated by free fatty acids (FFA) but show distinct structure
activity relationships for different chain lengths with short-chain
fatty acids (SCFAs, six or fewer carbon molecules) activating FFAR2
and FFAR3, and medium- and long-chain fatty acids activating
FFAR1 [2]. FFAR2 can couple to both Gai and Gaq [3,4] and is acti-
vated by C2 (acetate) and C3 (propionate) SCFAs [3,5].
Given the important physiological effects of FFAs, this subfamily
of receptors has sparked great interest in recent years as a poten-
tial source of novel targets for various diseases [6]. FFAR2 expres-
sion has been reported to be enriched in islets, a subset of immune
cells, adipocytes, and the gastrointestinal tract, suggesting its po-
tential role in various inﬂammation and metabolic conditions [3–
7]. Indeed, we have recently shown that activation of FFAR2 results
in inhibition of adipocyte lipolysis in vitro and reduction of plasma
FFA levels in vivo [7]. Since another GPCR, the nicotinic acid recep-
tor (GPR109A) [8] mediates similar effects in adipocytes we spec-
ulated the potential utility of targeting FFAR2 for treatingchemical Societies. Published by Eunderstanding of the receptor function and ligand binding will
facilitate the development of potential therapeutic molecules tar-
geting this receptor.
FFAR1 has attracted considerable attention given its well-estab-
lished effects on pancreatic b-cell function and its potential utility
in diabetes treatment [9,10]. Molecular modeling and mutagenesis
studies have identiﬁed several charged residues located in trans-
membrane domains (TM) 5, 6, and 7 that are important for anchor-
ing carboxylate groups in long chain fatty acids [11,12]. Not much
is known about ligand interactions with FFAR2 and FFAR3; analy-
ses based on FFAR1 ligand binding information have suggested
the potential importance of conserved polar residues in TMs 5, 6,
and 7 of FFAR2 and FFAR3 for endogenous ligand binding and func-
tion [13,14]. However, more deﬁnitive studies are required to pro-
vide greater insight into the mode of action and ligand binding
sites for FFAR2.
Herein, we report the results of mutagenesis studies to identify
important residues for orthosteric ligands induced receptor activa-
tion as well as their effects on interaction with allosteric ligands.
2. Materials and methods
2.1. Materials
Reagents were purchased from various sources as follows: so-
dium acetate from Sigma (St. Louis, MO), propionate from Flukalsevier B.V. All rights reserved.
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Fig. 1. Mutagenesis analysis of putative acetate binding site on FFAR2 receptor. (A) Molecular model of FFAR2 showing residues in the putative acetate binding site as well as
residues in the D(E)RY motif. (B) Molecular model of putative acetate binding site on FFAR2. Salt bridge interactions between the carboxylate anion of the acetate and residues
R180 and R255 are shown. (C–F) Wild type or mutant FFAR2 receptors were transiently transfected into CHO cells. Effects of mutations R255A and R180A on (C) acetate
activity and (D) on AMG7703 activity in the aequorin assays. Effects of mutations R255A and R180A on (E) acetate activity and (F) on AMG7703 activity in IP accumulation
assays. (G) Chemical structure of allosteric agonist AMG7703. (H) Cell surface expression levels of FLAG-tagged FFAR2 wild type and mutant receptors by ﬂow cytometry.
G. Swaminath et al. / FEBS Letters 584 (2010) 4208–4214 4209Chemie (Taufkirchen, Germany), coelenterazine from P.J.K. GmbH
(Kleinblittersdorf, Germany), polyethylenimine from Polysciences
(Warrington, WI). Hank’s buffered salt solution (HBSS), Free-style
medium and Pluronic F68 from Invitrogen (Carlsbad, CA),AMG7703 (previously known as Phenylacetamide 1) [14] was syn-
thesized at Amgen, Inc. (South San Francisco, CA). The detailed syn-
thetic routes, solubility properties of AMG7703, and SAR studies
have been described elsewhere [15].
4210 G. Swaminath et al. / FEBS Letters 584 (2010) 4208–42142.2. Cloning and site-directed mutagenesis of FFAR2
The cDNA for FFAR2 was subcloned in pcDNA 3.1 (Invitrogen,
CA). For the addition of a FLAG tag at the N-terminus, the FFAR2
cDNA was subcloned in pCMV-FLAG (Sigma–Aldrich, MO). Muta-
tions were made by using the site-directed mutagenesis kit from
Stratagene Inc. (La Jolla, CA) and the mutated sequence was veri-
ﬁed by sequencing.2.3. Aequorin assay
CHOK1 cells (2  106 per dish) were seeded in 145 mm
dishes and cultured with media containing DMEM-F12 and
10% FBS. The cells were incubated at 37 C, with 5% CO2 over-
night and transfected with 5 lg pcDNA3.1 FFAR2 and 5 lg
pcDNA3.1 aequorin vector constructs on the following day.
At 24 h after transfection, the cells were detached in PBS con-
taining 1 mM EDTA, loaded with coelenterazine, and assayed
as described previously [14].2.4. Inositol phosphate accumulation assay (IP assay)
HEK293-6E cells were cultured in free-style medium supple-
mented with 10% FBS, 0.1% Pluronic F68. In all, 20 ml of HEK293-
6E cells (containing 1  106 cells/ml) was transiently transfected
with 20 lg of vector DNA expressing FFAR2 using 60 ll of poly-
ethylenimine reagent (stock concentration of 1 mg/ml, pH 6.0) in
a 125-ml shaker-ﬂask. After 24 h of transfection, around 50 000
cells/well were seeded in a 96-well plate and labeled with [3H]
myoinositol for 16 h. The cells were then treated for 1 h at 37 C
with serial dilutions of test compounds in HBSS containing
25 mM HEPES (pH 7.4), 10 mM LiCl, and 0.01% HSA. Cells were
lysed with 20 mM formic acid for 4 h at 4 C. Ysi-SPA beads were
added to the cell lysates and incubated overnight in the dark.
Radioactivity was recorded on a Microbeta scintillation counter
(Perkin–Elmer).Table 2
Changes in potency (log EC50) of FFAR2 mutants in response to acetate and AMG7703
compared with wild type receptor in the IP accumulation assay. Data are aver-
aged ± S.E.M of three independent experiments performed in duplicate.
Constructs Acetate AMG7703
Log EC50 Delta Log EC50 Log EC50 Delta Log EC50
WT 3.3 ± 0.11 5.9 ± 0.05
E106A 2.5 ± 0.67 0.8* 4.6 ± 0.23 1.3*
Y108A Inactive Inactive
R180A Inactive 5.3 ± 0.0 0.6*
R255A Inactive 5.7 ± 0.06 0.2
* P value <0.05 was calculated using Dunett test.
Table 1
Changes in potency (log EC50) of FFAR2 mutants in response to acetate and AMG7703
compared with wild type receptor in the aequorin assay. Data are averaged ± S.E.M of
three independent experiments performed in duplicate.
Constructs Acetate AMG7703
Log EC50 Log EC50 Delta Log EC50
WT 2.8 ± 0.12 6.1 ± 0.06
E106A Inactive 4.6 ± 0.1 1.5*
Y108A Inactive Inactive
R180A Inactive 4.3 ± 0.05 1.8*
R255A Inactive 4.8 ± 0.16 1.3*
* P value <0.05 was calculated using Dunett test.2.5. FACS analysis
CHOK1 cells were seeded in 6-well Falcon Primaria plates (Bec-
ton Dickinson) at a density of 200 000 cells per well and incubated
overnight at 37 C and 5% CO2. Next day, the cells were transfected
with 2 lg per well with FLAG-tagged FFAR2 wild type or mutant
constructs using Lipofectamine 2000 (Invitrogen) according to
the manufacture’s protocol. The cells were harvested with phos-
phate buffer saline containing 2 mM EDTA and the pellet was
gently resuspended in 100 lL primary antibody staining solution
using a monoclonal anti-FLAG M2 antibody (Sigma) or mIgG
(MOPC21) isotype control (Sigma) at 10 lg/ml in ice cold FACS-
buffer (phosphate buffer saline with 2 mM EDTA and 2% fetal bo-
vine serum). Primary antibody staining was carried out on ice for
45 min, followed by 2 times washes with phosphate buffer saline
with 2 mM EDTA.
This was followed by secondary antibody staining in 100 lL
per reaction FACS-buffer containing a polyclonal goat-anti-
mouse F(ab0)2 fragment conjugated to FITC (DacoCytomation)
at 40 lg/ml on ice for 45 min followed by washes. The cells
were resuspended in 0.5 ml FACS-buffer and analysed using
a Beckman Coulter Cytomics FC500 FACS analyser. Geo-mean
values of anti-FLAG stained samples were analysed and com-
pared to the corresponding mIgG isotype sample controls.
Mean of three individual transfection performed on different
days were used to calculate the average Geo-mean represented
in Fig. 1.2.6. Molecular modeling
Molecular modeling was carried out as previously described
[14]. In brief, the sequence alignment and homology model were
generated using PRIME [16] as implemented in Maestro [17]. The
coordinates of the human b2-adrenergic receptor were used as
template for model building [18]. Side-chain and loop optimization
was performed using PRIME. Flexible docking was performed using
the Induce Fit Docking protocol as implemented in Maestro.
2.7. Data analysis
All results were presented as means ± S.E.M. of three indepen-
dent experiments each performed in duplicate. The maximal func-
tional response is expressed as percentage of the wild type
response for acetate and AMG7703. The data was ﬁtted to a four
parameter logistic equation using non-linear regression analysis
using Prism 5.01 (Graph-Pad Software Inc., San Diego, CA). The
cooperativity factors were calculated using the allosteric global
pEC50 equation as previously described [14].
3. Results
3.1. Identiﬁcation of acetate binding pocket
To identify the putative binding site for endogenous ligands, we
constructed a molecular model of FFAR2 based on homology mod-
eling using the X-ray crystal structure of the human b2-adrenergic
receptor as a template (Fig. 1A) [14,18]. This model revealed a po-
tential acetate binding site shown in Fig. 1B, in which the carbox-
ylic moiety was interacting with the conserved polar residues R180
(TM5) and R255 (TM7), and the aliphatic chain was oriented to-
ward a shallow hydrophobic pocket formed by residues from
TM6 and TM7. To experimentally test this prediction, mutations
of these two key residues were constructed and the mutant recep-
tors completely lost the acetate-induced activation in both aequo-
rin (Fig. 1C) and IP accumulation (Fig. 1E) assays. Consistent with
G. Swaminath et al. / FEBS Letters 584 (2010) 4208–4214 4211these results, both R180A and R255Amutant receptors also lost the
ability to respond to propionate induced receptor activation (data
not shown).
We have recently reported the identiﬁcation of a series of small
molecule phenylacetamides as novel allosteric agonists for FFAR2
[14,15]. To rule out the effects of the mutations on acetate activity
are not due to artifacts such as disruption of proper receptor fold-
ing or altered conformation, we tested a representative compound,
AMG7703 (Fig. 1G, previously called Phenylacetamide 1 [14]) on
these mutant receptors. In contrast to their effects on acetate, these
mutations modestly right shifted AMG7703-induced receptor acti-
vation in the transient aequorin assay (Fig. 1D and Table 1), while
having no signiﬁcant effects on AMG7703 activity in the IP accu-
mulation assay at steady state (Fig. 1F and Table 2). FACS analysis
was performed using N-terminal FLAG-tagged receptors to exam-
ine whether the potency changes were associated with the relative
expression levels of wild type and mutant receptors on cells. As
shown in Fig. 1H, both mutants had similar expression levels com-
pared to wild type receptor. Therefore, the selective abolishment of
acetate activity by these two mutations supports the idea that the
putative binding pocket between TM5, 6, and 7 is the site for direct
binding of acetate to the receptor. We found no differences in both-7 -6 -5 -4 -3 -2 -1
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Fig. 2. Allosteric modulations between acetate and AMG7703 on wild type and mutant r
aequorin assay on the wild type receptor (A and B), R180A mutant receptor (C and D), apotencies and maximal responses of the ligands to the FLAG-
tagged vs. untagged wild type receptors (data not shown). There-
fore, untagged receptors were used for further analyses which rep-
resent functional response closer to the physiological state of the
receptor.
We have shown previously that AMG7703 is an allosteric ago-
nist and shows a positive cooperativity with acetate (Fig. 2A,
[14]) with log a of 0.96 ± 0.22 and the reciprocal addition of acetate
to AMG7703 displays similar positive cooperativity (log a of
0.99 ± 0.17, Fig. 2B). To further explore how mutant receptors af-
fect acetate activity, we next examined allosteric interactions be-
tween endogenous and synthetic ligands on these two mutant
receptors. The addition of AMG7703 to acetate concentration re-
sponse curves and reciprocal addition revealed different responses
on the two mutant receptors. With respect to the R180A mutant,
acetate appeared to have antagonized receptor response to
AMG7703 (Fig. 2C). However, these effects were observed only at
high acetate concentrations (100–200 mM), and therefore, this
could be the result of potential assay artifacts. At lower concentra-
tions, acetate did not produce any signiﬁcant effects on AMG7703
concentration responses (Fig. 2C and D). In contrast to R180A mu-
tant, synthetic ligand AMG7703 appeared to have partially rescuedB
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eceptors. Allosteric effects between acetate and AMG7703 were characterized in the
nd on the R255A mutant receptor (E and F).
4212 G. Swaminath et al. / FEBS Letters 584 (2010) 4208–4214acetate function on the R255Amutant, as indicated by the ability of
acetate to activate receptor function in the presence of increasing
concentrations of AMG7703 (Fig. 2E). These results suggest that
R180 may play a more important role in anchoring the acidic head
group of acetate in the binding pocket than R255 and/or alterna-
tively, R180 may also be important for allosteric interactions be-
tween ortho- and allosteric sites.
3.2. Effects of D(E)RY motif on acetate activity
We next explored conserved residues known to affect GPCR
function on acetate-induced activation of the receptor. FFAR2 also
contains a highly conserved D(E)RY motif as in other Class A GPCRs
at the bottom of TM3. Several studies have implicated this motif as
being important for receptor conformation and ligand function. To
test the contribution of these residues to ligand function and allo-
steric interactions, mutant receptors containing E106A or Y108A in
the D(E)RY motif were generated. Both of these mutations have
signiﬁcant effects on both acetate and AMG7703 function. For
example, a loss of potency of over 10-fold was observed for
AMG7703 in E106A, and a complete loss of activity for both ligands
was observed in the Y108A mutant receptor. These data stronglyA
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Fig. 3. Effects of mutations in the D(E)RY motif of FFAR2 receptor on ligand function
transfected into CHO cells. The effects of receptor mutations E106A and Y108A on acet
mutations E106A and Y108A on AMG7703 activity in (B) aequorin and (D) IP accumulati
mutant. (F) Allosteric effect of acetate on AMG7703 concentration response curves measuggest the importance of the D(E)RY motif in FFAR2 receptor
function (Fig. 3 and Tables 1 and 2). Since a partial response of
the E106A mutant receptor to AMG7703 and acetate was still ob-
served, we tested its effects on allosteric interactions between
the two ligand binding sites. Interestingly, both ligands were able
to rescue the response of the mutant receptors with respect to each
other and they were also able to maintain positive allosteric inter-
actions (Fig. 3E with log a of 1.85 ± 0.066 and 3F with log a of
1.08 ± 0.063).
4. Discussion
In this report, we have studied residues important for the func-
tion of endogenous orthosteric ligand, acetate, and its interaction
with a newly identiﬁed synthetic allosteric agonist on FFAR2. We
ﬁrst explored a potential acetate binding site revealed in a model
of FFAR2 built based on the X-ray crystal structure of the human
b2-adrenergic receptor. The putative acetate binding pocket pre-
dicted by the model is partly formed by polar residues R180 and
R255 in TMs 5 and 7, respectively. These two residues are con-
served in the FFAR1 receptor, and the corresponding residues in
FFAR1 have been predicted to act as anchors for the carboxylic-10 -9 -8 -7 -6 -5 -4 -3
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and allosterism. Wild type or various mutant FFAR2 receptors were transiently
ate activity in (A) aequorin and (C) IP accumulation assays. The effects of receptor
on assays. (E) AMG7703 induces positive cooperativity on acetate binding to E106A
sured in aequorin assay on the E106A mutant receptor.
G. Swaminath et al. / FEBS Letters 584 (2010) 4208–4214 4213moiety of the endogenous ligands. Consistent with this, mutation
of these two residues in FFAR2 also abolished acetate activity, indi-
cating that these charged residues may also be critical for acetate/
receptor binding by directly interacting with the carboxylic head
group (Fig. 1). In addition, the selective abolishment of acetate,
but not the synthetic ligand’s activities, by these two mutations
provides further support for the direct role of this pocket in acetate
binding. Interestingly, we observed a partial rescuing of the acetate
activity in the presence of AMG7703 with the R255A mutant
(Fig. 2). The ability of an allosteric ligand to rescue a defective
mutation in the orthosteric binding site was somewhat unex-
pected. However, since such rescuing was not observed with the
R180A mutant receptor (Fig. 2), this suggests that R180 may play
a more important role than R255 in anchoring the acidic head
group of acetate in the binding pocket, and the lack of response
of R180A mutant receptor to acetate in either the presence or ab-
sence of AMG7703 may due to lack of effective acetate binding
to R180A.
Previous experimental studies, supported by the rhodopsin
crystal structure, have suggested that the well-conserved D(E)RY
motif in class A GPCRs is involved in maintaining the receptor in
the ground state [19,20]. It has been proposed that mutation of
the glutamic/aspartic acid of the D(E)RY motif would reposition
the arginine from its polar pocket, resulting in the ability of some
GPCRs to adopt an active (R*) conformation [21,22]. However, the
loss of activity on mutation of the corresponding aspartate has also
been observed with M1 and M5 ACHR, V1aR, CB2R, and CCR5
receptors [23]. FFAR2 contains ERY (106–108) at this location,
and mutation of E106 to alanine did not lead to any constitutive
activation of the receptor in the aequorin or IP assays (data not
shown). The mutation of both E106A and Y108A did affect the po-
tency and efﬁcacy of both the acetate and AMG7703 (Fig. 3), sup-
porting the concept of an important role for the D(E)RY motif in
stabilizing FFAR2 receptor conformation. Surprisingly, positive
cooperativity had been preserved in the E106A mutant,
AMG7703 was able to rescue the response of mutant receptor to
acetate (Fig. 3E and F) presumably through allosteric interaction.
The rescued response on the E106A mutant receptor to acetate
was stronger than the rescued response observed with R255A mu-
tant. The difference between the two mutants may be the result of
whether the mutated residues directly contribute to acetate bind-
ing. Since R255 may directly interact with the acidic head group of
acetate, the loss of electrostatic interactions in the R255Amutant is
unlikely to be completely compensated for by the allosteric effects
from AMG7703 binding. However, the effects of the E106A muta-
tion are only conformational since it is not in the direct acetate
binding pocket (Fig. 1A). Therefore, this kind of loss-of-function
mutation has the potential to be fully restored with the reversal
or compensatory conformational changes induced by an allosteric
ligand. These data further support the potential importance of allo-
steric agonists in a therapeutic setting and the possibility of iden-
tifying ligands that can activate seemingly inactive receptors that
might occur as SNPs [24,25].
In this study, we used mutagenesis to probe the putative bind-
ing site as well as other important residues for endogenous ligand
of FFAR2. In summary, the results support the proposed putative
acetate binding site formed by conserved polar residues in TM5,
6, and 7 as important for endogenous ligand binding. In recent
years, signiﬁcant progress in the rational design of allosteric mod-
ulators has been made for muscarinic acetylcholine, metabotropic
glutamate, adenosine and GABAergic receptors. Multiple allosteric
modulators displaying excellent subtype selectivity for M1 and M4
have been identiﬁed [26–28]. Our studies provide new insights not
only to the existence of different receptor conformations induced
by orthosteric or allosteric ligands, but also the ability of the allo-
steric ligand to rescue the orthosteric ligand in receptor activationmay provide further understanding of the dynamics of GPCR con-
formational states and the application to the development of novel
allosteric ligands.Acknowledgments
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